|
|
L. polysaccharide |
|
Vaxjo ID |
281 |
|
Vaccine Adjuvant Name |
L. polysaccharide |
|
Adjuvant VO ID |
VO_0005769
|
|
Description |
Polysaccharides derived from Artemisia rupestris L., traditionally used in Chinese medicine, shown to promote DC maturation and Th1/Th2 immune responses. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
CARP-1 and CARP-2 |
|
Structure |
Heteropolysaccharides mainly composed of galactose, arabinose, glucose, rhamnose and galacturonic acid. |
|
Preparation |
Extracted using hot water, ethanol precipitation, protein removal, dialysis, and DEAE-cellulose chromatography. |
|
Dosage |
Mice received 50 μg CARP-1 or CARP-2 subcutaneously with 10 μg OVA, in 50 μL formulation, twice at 2-week intervals. |
|
Function |
Two components (CARP-1 and CARP-2) were fractionated from cultivated Artemisia rupestris L. and then characterized by HPGPC and HPLC. |
|
Safety |
Non-cytotoxic to mouse splenocytes at 10–3200 μg/mL. No apparent adverse effects in vivo in vaccinated mice. |
| References |
Li et al., 2022: Li Q, Weng X, Zhao B, Yang Y, Zhang A. Immunoregulatory properties of the cultivated Artemisia rupestris L. polysaccharide as a potential adjuvant. Carbohydrate polymers. 2022; 291; 119525. [PubMed: 35698367].
|
|
